ArticleInternational journal of molecular sciences2025
Therapeutic Effects of Lurbinectedin in PARP Inhibitor-Resistant High-Grade Serous Ovarian Cancer Using Patient-Derived Cell Lines and Organoid Models.
Akshi Srivastava et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.